Announced Fri, 29 May · 14:28 IST

Audited financial results for the quarter and year ended 31.03.2026

Pat Growth 25pctRevenue Growth 20pctNegative Operating CashflowResults View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-9.6%1-day move
₹85.95
prior close
₹87.49
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.0-2.1-2.1-1.2-9.6-10.5-10.6-9.9-9.5-8.7-5.8-6.5
Up moveDown movePending
AI summary

Jeevan Scientific Technology reported strong audited results for FY26. Standalone revenue grew 23.7% to Rs 5,393.13 lakhs from Rs 4,360.99 lakhs, while consolidated revenue rose 31.4% to Rs 6,153.71 lakhs from Rs 4,684.36 lakhs. Standalone PAT jumped 124% to Rs 165.01 lakhs from Rs 73.67 lakhs, and consolidated PAT surged to Rs 103.33 lakhs from just Rs 5.90 lakhs. EPS improved significantly - standalone basic EPS increased from Rs 0.47 to Rs 0.83. The company raised capital via preferential allotment of 40.85 lakh equity shares and 35 lakh convertible warrants. Statutory auditors issued an unmodified (clean) opinion for both standalone and consolidated results. The company operates in Clinical Research Services segment.

Likely market impact

The company delivered exceptional PAT growth exceeding 100%, significantly outpering typical benchmarks and signaling strong operational performance. The clean audit opinion with improving profitability and positive operating cash flow (Rs 255.50 lakhs standalone) is positive for shareholders. The significant equity raise reduces near-term balance sheet pressure.